Core Viewpoint - A class action has been filed against Fortrea Holdings, Inc. for allegedly misleading investors regarding the progress of its pre-spin projects and financial expectations following its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings, Inc. is a global contract research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [1]. - The company was spun off from Labcorp Holdings Inc. in June 2023 and entered into transition services agreements (TSAs) with Labcorp for various support services [2]. Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not meeting prior expectations, indicating that pre-spin projects were underperforming [3]. - The company reported that its pre-spin projects were "late in their life cycle" and had lower revenue and profitability than anticipated for 2025, leading to a significant stock price drop of 25.05% to $10.38 per share [3]. Group 3: Allegations and Misstatements - The complaint alleges that Fortrea overestimated the revenue contributions from pre-spin projects and overstated potential cost savings from exiting TSAs, inflating its EBITDA targets for 2025 [4]. - It is claimed that the viability of Fortrea's post-spin business model and financial prospects were also overstated during the class period [4].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea Holdings Inc. is a global clinical research organization (CRO) that provides biopharmaceutical product and medical device development solutions to various customers [2]. - The company was spun off from Labcorp Holdings Inc. in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit alleges that Fortrea overestimated revenue contributions from pre-spin projects, overstated cost savings from exiting transition services agreements (TSAs), and inflated its EBITDA targets for 2025 [3]. - Specific claims include that Fortrea's business model viability and financial prospects were overstated, leading to significant stock price declines following negative reports from analysts [3][4][5]. Stock Performance and Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model, resulting in a stock price drop of over 12% [4]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral from outperform on December 6, 2024, leading to an additional stock price decline of over 8% [5]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, causing a stock price drop of more than 25% [6]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Fortrea securities during the class period to seek appointment as lead plaintiff in the lawsuit [7]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [8].

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - The class action lawsuit has been filed against Fortrea Holdings, alleging that the company made false and misleading statements regarding its revenue projections and cost savings, which inflated its EBITDA targets for 2025 [4]. - Investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible for compensation [1][4]. - A lead plaintiff must file a motion with the court by August 1, 2025, to represent other class members in the litigation [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [3].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between July 3, 2023, and February 28, 2025, impacting investors adversely [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fortrea Holdings Inc. overestimated revenue contributions from its long-term projects, known as the Pre-Spin Projects, for the year 2025 [2]. - It is alleged that the company overstated potential cost savings from exiting transition services agreements, leading to inflated EBITDA targets for 2025 [2]. - The viability of Fortrea's post-spin-off business model and its financial prospects were reportedly overstated, resulting in materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 1, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing significant recoveries for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fortrea Holdings Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by August 1, 2025 [3][5]. Group 1: Allegations Against Fortrea - The complaint alleges that Fortrea and its executives made false and misleading statements regarding revenue expectations from Pre-Spin Projects and overstated cost savings from exiting Transitional Service Agreements (TSAs) [5]. - It is claimed that Fortrea's previously announced EBITDA targets for 2025 were inflated, leading to an overstatement of the company's business model viability and financial prospects [5]. - The company's public statements were deemed materially false and misleading at all relevant times [5]. Group 2: Stock Performance and Analyst Downgrades - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in the business model and a stock price drop of $2.73 per share (12.29%) to close at $19.48 [6]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral on December 6, 2024, resulting in a stock price decline of $1.90 per share (8.06%) to close at $21.67 [7]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, leading to a significant stock price drop of $3.47 per share (25.05%) to close at $10.38 [8]. Group 3: Legal Proceedings and Investor Actions - Investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1][3]. - The court-appointed lead plaintiff will be the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [9]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Fortrea's conduct [10].

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=152588&from=3 CLASS PERIOD: Ju ...

Core Viewpoint - Fortrea has adopted a limited-duration stockholder rights plan to protect the long-term value for all stockholders and ensure fair treatment in potential takeover situations [1][2][3] Summary by Sections Rights Plan Purpose - The Rights Plan aims to enable stockholders to realize long-term investment value and ensure fair treatment during any proposed takeover [2] - It is designed to prevent tactics that could allow control of the Company without appropriate compensation to all stockholders [2] - The plan was initiated in response to significant dislocation in the trading price of the Company's stock and interest from third parties to capitalize on this dislocation [2] Rights Plan Details - The Rights Plan applies equally to all current and future stockholders and does not deter offers or preclude the Board from considering beneficial transactions [3] - Fortrea will issue one right for each share of common stock as of June 23, 2025, with rights becoming exercisable if any person acquires 10% or more of the outstanding common stock [4] - If exercisable, rights holders (excluding the triggering person) can acquire shares at a 50% discount or exchange rights for one share of common stock [4] - The Board can redeem the rights at $0.001 per right, and the plan does not limit future Boards' ability to redeem the rights [4] Company Overview - Fortrea is a leading global provider of clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [6] - The Company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [6]

NEW YORK, June 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE).Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=152581&from=4CLASS PERIOD: July 3, 20 ...